Literature DB >> 29572792

Development of the Histoculture Drug Response Assay (HDRA).

Robert M Hoffman1,2, Robert A Vescio3.   

Abstract

The histoculture drug response assay (HDRA) was developed using Gelfoam® histoculture of all tumor types. Twenty tumor classes, including all the major ones, have been histocultured on Gelfoam® and tested for drug response. Quantitative and qualitative results show increasing cell kill with rising cytotoxic drug concentration, differential drug sensitivities of multiple cell types within individual cultured tumors, differential sensitivities to a single drug of a series of tumors of the same histopathological classification, differential sensitivities of individual tumors to a series of drugs, and sensitivity patterns of various tumor types similar to the sensitivities found in vivo. Therefore, the results indicated that precise therapeutic data can be obtained from tumor specimens growing in Gelfoam® histoculture in vitro for the individual cancer patient as well as for rational and relevant screening for novel agents active against human solid tumors.

Entities:  

Keywords:  3D Gelfoam® culture; Drug response; Patient tumors; Personalized therapy; Precision oncology

Mesh:

Substances:

Year:  2018        PMID: 29572792     DOI: 10.1007/978-1-4939-7745-1_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Co-implantation of Tumor and Extensive Surrounding Tissue Improved the Establishment Rate of Surgical Specimens of Human-Patient Cancer in Nude Mice: Toward the Goal of Universal Individualized Cancer Therapy.

Authors:  Takuya Murata; Chihiro Hozumi; Yukihiko Hiroshima; Koichiro Shimoya; Atsushi Hongo; Sachiko Inubushi; Hirokazu Tanino; Robert M Hoffman
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

2.  Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high-grade serous carcinoma.

Authors:  Naoki Kojima; Hiroshi Yoshida; Ikumi Kuno; Takashi Uehara; Masaya Uno; Mitsuya Ishikawa; Tomoyasu Kato
Journal:  Cancer Med       Date:  2019-06-26       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.